- Details
- Continence Nurse Practitioner and Biofeedback-Certified Specialist, Diane Newman presents Urinary Symptoms Post-Prostatectomy Case Study of a 68-year old male with long-term lower urinary tract symptoms, treated for many years for BPH who had a robotic-assisted radical prostatectomy after being diagnosed with prostate cancer. Biographies: Diane K. Newman, DNP FAAN BCB-PMD , Urologic Nurse Practiti...
|
- Details
- Continence Nurse Practitioner and Biofeedback-Certified Specialist, Diane Newman presents on one of the most challenging complications and an independent predictor of global quality of life, post-prostatectomy incontinence. Biographies: Diane K. Newman, DNP FAAN BCB-PMD , Urologic Nurse Practitioner, Adjunct Professor of Urology in Surgery Research Investigator Senior, Perelman School of Medicine,...
|
- Details
- John Feller presents at the Focal Therapy and Imaging in Prostate and Kidney Cancer Symposium, sharing interim 10-year results of the Phase II trial of Laser Focal Therapy for prostate cancer. This involves an outpatient trans-rectal laser therapy guided with an MRI imaging system. 95% of patients were biopsy compliant at 6 months and 94% avoided whole gland therapy and associated morbidity. The r...
|
- Details
- Prostate cancer survivor John Fortin is joined by Art Rastinehad a professor of urology and radiology at Mount Sinai to discuss targeted therapies for prostate cancer. Together they discuss when patients are recommended to active surveillance, versus when they must receive more complex treatment regimes. They discuss the research done to identify and test focal therapies for prostate cancer. Dr. R...
|
- Details
- Tom Polascik, a urologic oncologist with considerable experience in treating both kidney and prostate cancer and the founder of the Focal Therapy Society joins John Fortin providing a background of the Focal Therapy society and the 12th International Symposium on focal therapy and imaging in prostate and kidney cancer. He shares the concept of the society and summarizes the evolution of care in pr...
|
- Details
- Matthew Allaway, CEO of Corbin Clinical Resources, surveys the relative benefits of transperineal versus transrectal prostate biopsy. Although transrectal ultrasound-guided prostate biopsy has been the standard for prostate cancer diagnosis since the 1980s, recent studies have revisited the transperineal approach due to the incidence of infectious and sepsis complications and missed cancer diagnos...
|
- Details
- Lorelei Mucci and Elizabeth Platz join Charles Ryan in a discussion on the impact of vitamin D and statins on prostate cancer outcomes. There is no direct evidence linking vitamin D and the risk of prostate cancer, however, vitamin D is believed to be important for overall good health. There is an inverse relationship between cholesterol and risk for the development of prostate cancer and statin u...
|
- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat 2019 (PCF 2019), Stacey Kenfield joins Charles Ryan to speak about her work on lifestyle, exercise, nutrition and its impact on prostate cancer. She talks about the Prostate 8 program which resulted from looking at men with prostate cancer and studying different dietary and lifestyle factors that might be associated with prostate can...
|
- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat 2019 (PCF 2019), Professor June Chan joins Charles Ryan to discuss her study "Eat, Move, Sleep," a digital cohort study that is focused on cancer survivorship aiming to collect data on diet, exercise, sleep, and other lifestyle practices in people with prostate, colorectal, and/or bladder cancer. This study is set to open in early 20...
|
- Details
- In this conversation, Neeraj Agarwal joins Petros Grivas to discuss the Patient-Reported Outcomes (PRO) data from the TITAN study, Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. This data was presented at ESMO 2019. The Food and Drug Administration approved apalutamide (ERLEADA, Janssen Biotech, Inc) for patients with metastatic hormone-sensitive prostate cancer. (mHSPC) in Sept...
|
